Probiotic-based therapy for pulmonary arterial hypertension (PAH): Bifidobacterium lactis LKM512-containing yogurt inhibits the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3, 17/November/2018, 12.11 am

Valproic acid-based therapy for blood sugar disease: Valproic acid  increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 16/October/2018, 11.57 pm
November 16, 2018
Curry’s main ingredient/ coloring agent Curcumin may extend the lifespan of humans: Curcumin-based Lifespan extension therapy: Curcumin, found in turmeric,  inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian lifespan by regulating the expression of its target genes, 17/November/2018, 8.16 am
November 17, 2018
Show all

What they say: 

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054],  by Prof. Thistlethwaite PA, Li X and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:

Probiotic-based therapy for pulmonary arterial hypertension (PAH)Bifidobacterium lactis LKM512-containing yogurt inhibits the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3


The significance of the study:  

This study suggests, for the first time, that Bifidobacterium lactis LKM512by increasing the expression of its target gene, it may decrease, in a dose-dependent manner, the expression of Notch3 and its target gene Hes-5 (Fig.1). Thereby, it may inhibit and promote, respectively, proliferation and differentiation of smooth muscle cells. And, thereby, prevent pulmonary hypertension (Figure 1).  Thus, pharmacological formulations encompassing Bifidobacterium lactis LKM512either alone or in combination with other drugs,” may be used to treat pulmonary arterial hypertension (Figure 2).

Figure 1. Mechanistic insights into how Probiotic Bifidobacterium lactis LKM512 inhibits the development of pulmonary hypertension through regulation of its target genes

Figure 1. Mechanistic insights into how Probiotic Bifidobacterium lactis LKM512 inhibits the development of pulmonary hypertension through regulation of its target genes


Details of the research findings: 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Undisclosed mechanistic information: How does Bifidobacterium lactis LKM512-containing yogurt decrease the expression of Notch3 and its target gene?

Amount: $500#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L.,  Probiotic-based therapy for pulmonary arterial hypertension (PAH)Bifidobacterium lactis LKM512-containing yogurt inhibits the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3, 17/November/2018, 12.10 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Comments are closed.